VRTX Stock Vertex Pharmaceuticals Incorporated
BUY US · NasdaqGSRare-disease dominance and new product launches support high-quality earnings durability.
Future value: $571.46 (+10.43%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Pipeline launches and strong institutional-quality fundamentals.
- ▾Below 50-day MA (-1.04%)
- ▸Above 200-day MA — long-term uptrend
Is VRTX a buy right now?
Trend: VRTX is trading below the 50-day average (-1.04%), RSI 50 — neutral momentum, with a 3-month return of +5.53%.
Valuation & quality: Vertex Pharmaceuticals Incorporated trades on a trailing P/E of 30.1, forward P/E 25.3, PEG 2.05, price-to-book 6.48; fundamentals show net margin 35.0%, return on equity 23.5%, revenue growth 12.5% year on year.
Analyst consensus: 28 analysts have a mean 12-month price target of $571.46 (+10.4% vs the last close; range $350.00 – $667.00), consensus rating “buy”.
Our screen: BUY (score 2) — Rare-disease dominance and new product launches support high-quality earnings durability.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -10.10% | -4.30% | +4.70% | +11.00% | -4.00% | +14.10% | -4.00% | -1.00% |
Fundamentals
Analyst price target
Technical signals
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally.
Sector: Healthcare · Industry: Biotechnology · United States · 6,400 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.